Clinical Trial Update: An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 trial update for the 6-valent OspA-based Lyme disease vaccine VLA15 indicates the study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Disease

Drugs mentioned

• VLA15

Snippet

Sponsor: Pfizer | Conditions: Lyme Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING